Core Viewpoint - The company, Fulejia, is experiencing a decline in revenue and net profit for the first half of 2025, but there are signs of recovery in the second quarter due to sales channel optimization and product price adjustments [1][2]. Group 1: Financial Performance - For the first half of 2025, the company reported a revenue of 863 million yuan, a year-on-year decrease of 8.15% [1] - The net profit attributable to shareholders was 230 million yuan, down 32.54% year-on-year [1] - The net profit after excluding non-recurring gains and losses was 166 million yuan, a decrease of 48.66% year-on-year [1] - Basic earnings per share were 0.44 yuan [1] Group 2: Sales Channels and Strategies - The company has implemented a multi-channel sales strategy, integrating online and offline sales, covering major e-commerce platforms like Tmall, Douyin, JD.com, and Pinduoduo, as well as offline medical institutions and retail stores [1] - In the second quarter of 2025, the company saw a significant revenue increase of 86.68% compared to the first quarter, indicating a recovery in performance [2] - The company is focusing on optimizing offline distribution channels, with over 99% of revenue coming from the distribution model, which incurs minimal sales expenses [2] Group 3: Product Development - The company is enhancing its product line, particularly in non-patch products, with a steady increase in their revenue share [3] - The establishment of a research and development center in Shanghai is expected to accelerate product innovation and expansion [3] - The company has completed the third round of injections for a project involving humanized collagen freeze-dried fibers, which is currently in the data cleaning and report preparation stage [3]

Core Insights - The local life service market in China is undergoing significant transformation, with projections indicating that the market size will exceed 35.3 trillion yuan by 2025, and online penetration is expected to reach 30.8% [4] - Weimob's multi-channel strategy aligns with the core trends of the industry, focusing on deepening its presence in local life services [4] Group 1: Multi-Channel Strategy - Weimob's multi-channel strategy is not merely about traffic migration but involves the WOS system to achieve multi-layer integration of "products, orders, and members" [6] - Merchants can manage product information across platforms through Weimob's backend, and cross-platform order management is facilitated, allowing for centralized oversight of orders from platforms like Meituan and Douyin [6] - Users are encouraged to register as Weimob members when redeeming vouchers, enhancing member value through a system of points, levels, and exclusive benefits [6] Group 2: Industry Ecosystem - The cross-platform collaboration promoted by Weimob is shifting the local life service industry from "traffic competition" to "user management" [6] - Public domain platforms excel in traffic acquisition but have limited user retention capabilities, while private domain operations are better at user retention but have higher customer acquisition costs [6] - Weimob connects these two aspects, enabling merchants to leverage the high efficiency of public domain customer acquisition and the significant value of private domain repurchases [6] Group 3: Future Outlook - Weimob aims to deepen cooperation with leading platforms to expand more redemption scenarios and service capabilities, fostering a business ecosystem of "traffic interconnection and value co-creation" [6] - As technology evolves and the ecosystem matures, Weimob's multi-channel layout is expected to drive local retail into an era of "refined operations" [6] - Weimob positions itself as a "super connector," providing critical support for the industry's evolution [6]

相关研究 [Table_OtherReport] 销售毛利率逐季提升，长期成长可期 核心品类同比增 30%+, 盈利能力提升 可期 五大产品线均衡发展, 听力保健成长 可期 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 聚焦核心品类，结构调整提升盈利能力 证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 可孚医疗(301087) | 投资评级 | 买入 | | --- | --- | | 上次评级 | 买入 | | 执业编号：S1500523080002 | | | --- | --- | | [Table_Author] 唐爱金 邮 | 医药行业首席分析师 箱：tangaijin@cindasc.com | 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com [Table_ReportDate] 2025 年 05 月 05 日 [Table_S 事件：公 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company focuses on core product categories, leading to significant growth in revenue and profitability. In 2024, the company achieved a revenue of 2.983 billion yuan, a year-on-year increase of 4.53%, with a net profit of 312 million yuan, reflecting a year-on-year growth of 22.60% [2][3] - The company has seen a balanced development across five major product lines, with the rehabilitation aids category being a major growth driver, achieving a revenue of 1.104 billion yuan, up 42.77% year-on-year [2] - The company is enhancing its mid-to-high-end product matrix and multi-channel layout, which is expected to open new growth opportunities. In 2024, online business revenue reached 1.990 billion yuan, an increase of 8.94% year-on-year [2] Financial Performance Summary - In 2024, the company reported a gross profit margin of 51.86%, an increase of 8.58 percentage points year-on-year, and a net profit margin of 10.47%, up 1.61 percentage points year-on-year [2] - The company forecasts revenues of 3.538 billion yuan, 4.148 billion yuan, and 4.846 billion yuan for 2025, 2026, and 2027 respectively, with corresponding year-on-year growth rates of 18.6%, 17.2%, and 16.8% [3][4] - The projected net profit for 2025, 2026, and 2027 is 398 million yuan, 485 million yuan, and 584 million yuan, representing year-on-year growth rates of 27.7%, 21.8%, and 20.3% respectively [3][4]